推荐产品
质量水平
方案
≥98% (TLC)
表单
powder
颜色
white to off-white
溶解性
H2O: soluble 19.60-20.40 mg/mL, clear, colorless to faintly yellow
methanol: 20 mg/mL, clear, colorless
ethanol: 4 mg/mL
创始人
Abbott
SMILES字符串
Cl[H].COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4
InChI
1S/C19H25N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H
InChI key
IWSWDOUXSCRCKW-UHFFFAOYSA-N
基因信息
human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146)
一般描述
盐酸特拉唑嗪用于治疗高血压和良性前列腺增生(BPH)。它在肝脏中代谢。它可能与头晕、头痛和虚弱有关。盐酸特拉唑嗪与急性全身性皮疹性脓疱病有关。
应用
盐酸特拉唑嗪已通过反相色谱研究用于正交性和相似性分析5。此外,特拉唑嗪还用于评估化学计量学技术,以确定色谱方法中的正交性和相似性6。
生化/生理作用
α1-肾上腺素受体拮抗剂。
制备说明
盐酸特拉唑嗪可溶于水,浓度为19.60 - 20.40 mg/ml,并产生一种透明无色至淡黄色的溶液。它也可溶于乙醇,浓度为4 mg/mL。此外,根据需要加热,该产品可溶于甲醇,浓度为20 mg/mL,并产生澄清无色的溶液。
警示用语:
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
历史批次信息供参考:
分析证书(COA)
Terazosin in the treatment of benign prostatic hyperplasia
Archives of Family Medicine, 2(9), 929-929 (1993)
Acute generalized exanthematous pustulosis caused by terazosin hydrochloride.
J. Drugs Dermatol., 7(4), 395-397 (2008)
Terazosin
Drugs, 33(5), 461-477 (1987)
Free radical biology & medicine, 163, 190-195 (2020-12-23)
Hyperthecosis syndrome is a common endocrine system metabolic disorder in women of childbearing age. The main symptoms are elevated androgen levels, abnormal ovulation, and excessive oxidative stress. Currently, there is no effective treatment for hyperthecosis syndrome. α(1)-adrenergic receptor (ADRA1) is
European journal of pharmacology, 294(2-3), 645-650 (1995-12-29)
The effects of i.v. infusion of the alpha1-adrenoceptor antagonists doxazosin and terazosin (2 mg kg-1 h-1) on spontaneous hypogastric, renal and inferior cardiac nerve activity, spontaneous bladder contractions, blood pressure, heart rate and femoral arterial flow were investigated separately in
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门